Edition:
United Kingdom

Aratana Therapeutics Inc (PETX.OQ)

PETX.OQ on NASDAQ Stock Exchange Global Market

4.42USD
17 Jul 2018
Change (% chg)

-- (--)
Prev Close
$4.42
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
104,727
52-wk High
$7.57
52-wk Low
$3.68

Latest Key Developments (Source: Significant Developments)

Aratana Therapeutics Files For FDA Approval Of Nocita Label Expansion
Friday, 1 Jun 2018 

June 1 (Reuters) - Aratana Therapeutics Inc ::ARATANA THERAPEUTICS FILES FOR FDA APPROVAL OF NOCITA® (BUPIVACAINE LIPOSOME INJECTABLE SUSPENSION) LABEL EXPANSION.ARATANA THERAPEUTICS INC - FDA'S ANIMAL DRUG USER FEE ACT REVIEW DATE IS SET FOR JULY 30, 2018 FOR NOCITA.  Full Article

Aratana Appoints Craig Barbarosh And Lowell Robinson To Board In Cooperation Agreement With Engaged Capital
Monday, 21 May 2018 

May 21 (Reuters) - Aratana Therapeutics Inc ::ARATANA THERAPEUTICS APPOINTS CRAIG BARBAROSH AND LOWELL ROBINSON TO ITS BOARD OF DIRECTORS IN COOPERATION AGREEMENT WITH ENGAGED CAPITAL.ARATANA THERAPEUTICS INC - FOLLOWING CHANGES, ARATANA'S BOARD HAS BEEN INCREASED TO TEN MEMBERS.ARATANA THERAPEUTICS INC - RIP GERBER, A MEMBER OF BOARD, HAS RESIGNED.ARATANA THERAPEUTICS INC - ENGAGED CAPITAL HAS AGREED TO WITHDRAW ITS PREVIOUSLY NOMINATED SLATE OF DIRECTORS FOR ELECTION AT ANNUAL MEETING.  Full Article

Aratana Therapeutics Granted Conditional License For A Canine Osteosarcoma Therapeutic
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Advaxis Inc ::ARATANA THERAPEUTICS GRANTED CONDITIONAL LICENSE FOR A CANINE OSTEOSARCOMA THERAPEUTIC.ARATANA THERAPEUTICS-U.S. DEPARTMENT OF AGRICULTURE CENTER FOR VETERINARY BIOLOGICS GRANTED CONDITIONAL LICENSE​ FOR CANINE OSTEOSARCOMA VACCINE,AT-014.  Full Article

Aratana Therapeutics Says Study Did Not Achieve Protocol-Defined Efficacy Success Criteria
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Aratana Therapeutics Inc ::ARATANA THERAPEUTICS ANNOUNCES STUDY RESULTS FOR AT-016.ARATANA THERAPEUTICS INC - ARATANA'S LICENSE PARTNER RESPONSIBLE FOR DEVELOPMENT OF AT-016 SHARED RESULTS OF A PIVOTAL STUDY.ARATANA THERAPEUTICS - RECEIVED TOP-LINE PIVOTAL FIELD EFFECTIVENESS STUDY RESULTS FOR AT-016.ARATANA THERAPEUTICS - PARTNER RESPONSIBLE FOR AT-016 SHARED RESULTS OF PIVOTAL STUDY, WHICH DID NOT ACHIEVE PROTOCOL-DEFINED EFFICACY SUCCESS CRITERIA.ARATANA THERAPEUTICS INC - AS PART OF CO'S EXCLUSIVE COMMERCIAL LICENSE FOR DOGS WITH OSTEOARTHRITIS IN U.S., CO FUNDED CLINICAL STUDY & OTHER WORK.ARATANA THERAPEUTICS - CO ANTICIPATES AFTER PARTNER EVALUATED STUDY RESULTS, PARTIES TO DETERMINE IF COLLABORATION TO BRING THERAPEUTIC TO MARKET TO CONTINUE.  Full Article

Aratana Therapeutics Announces Proposed Public Offering
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Aratana Therapeutics Inc ::ARATANA THERAPEUTICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING.ARATANA THERAPEUTICS INC - ‍COMMENCING AN UNDERWRITTEN REGISTERED PUBLIC OFFERING OF $35 MILLION OF SHARES OF ITS COMMON STOCK​.ARATANA THERAPEUTICS INC - ‍ALL OF SHARES ARE BEING OFFERED BY ARATANA THERAPEUTICS​.  Full Article

ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT IN EUROPE
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Elanco Animal Health::ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT® (GRAPIPRANT TABLETS) IN EUROPE.CO, ARATANA THERAPEUTICS ANNOUNCED EMA'S CVMP ADOPTED POSITIVE OPINION TO RECOMMEND MARKETING AUTHORIZATION OF GALLIPRANT IN EU.FOLLOWING THE POSITIVE OPINION, EC WILL COMPLETE REGULATORY PROCESS FOR FINAL DECISION ON MARKETING AUTHORISATION IN EARLY 2018.  Full Article

Aratana Therapeutics reports Q3 loss per share of $0.21
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Aratana Therapeutics Inc :Aratana Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.21.Q3 revenue $6.2 million.  Full Article

Aratana Therapeutics announces launch of Entyce
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Aratana Therapeutics Inc :Aratana Therapeutics announces launch of Entyce® (capromorelin oral solution).Aratana Therapeutics - co is making Entyce commercially available to veterinarians in United States for appetite stimulation in dogs​.  Full Article

Aratana Therapeutics granted FDA approval of Nocita
Monday, 15 Aug 2016 

Aratana Therapeutics Inc : Aratana Therapeutics granted FDA approval of Nocita® (bupivacaine liposome injectable suspension) .Anticipates Nocita will be commercially available to veterinarians in fall of 2016.  Full Article

Aratana posts Q2 EPS $0.61
Thursday, 4 Aug 2016 

Aratana Therapeutics Inc : Q2 earnings per share $0.61 . Aratana therapeutics reports second quarter 2016 financial results .Q2 revenue $38 million versus $45 million.  Full Article

BRIEF-Aratana Therapeutics Q1 Loss Per Share $0.19

* ARATANA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS